PDL-1 Targeting in Resectable Oesophageal Cancer

NCT03087864 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer, Stage II
Esophageal Cancer Stage III

Interventions

DRUG: Atezolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
RADIATION: Radiotherapy 23 x 1.8 Gy

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]